BOSTON, MA—Mintz advised client ArriVent BioPharma, Inc. (NASDAQ: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, on its initial public offering (IPO) on the Nasdaq Global Market. ArriVent priced an upsized IPO of 9,722,222 shares of its common stock at a public offering price of $18.00 per share. All of the shares of common stock were offered by ArriVent. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by ArriVent, were approximately $175 million. In addition, ArriVent granted the underwriters a 30-day option to purchase up to an additional 1,458,333 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.
Mintz advised ArriVent in the offering, with a capital markets team led by Members John Rudy and Matthew T. Simpson, with Associates Nishant Dharia, Raven Sun, Gianna Nappi, Elana Lerner Brockman, Sam Silver and Gretchen Goyette.